Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level ≥50 ng/mL

Brant A. Inman, Judson D. Davies, Laureano J. Rangel, Eric J. Bergstralh, Eugene D. Kwon, Michael L. Blute, R. Jeffrey Karnes, Bradley C. Leibovich

Research output: Contribution to journalArticle

39 Scopus citations


BACKGROUND. The authors evaluated the long-term outcomes of men with prostate cancer and very high (≥50 ng/mL) preoperative serum prostate-specific antigen (PSA) values that were treated with radical prostatectomy. METHODS. This study included 236 men with preoperative serum PSA values ≥50 ng/mL who underwent radical retropubic prostatectomy between 1987 and 2004. For comparison, the study cohort was divided into 2 groups: patients with PSA levels between 50 and 99 ng/mL and patients with PSA levels ≥100 ng/mL. Biochemical recurrence was defined as a single postoperative serum PSA value of 0.4 ng/mL or greater. Systemic disease progression was defined as the development of a local recurrence or systemic metastases, and any death resulting from prostate cancer or its treatment was defined as a cancer-specific mortality. RESULTS. Biochemical recurrence-free survival rates in the groups of patients with a PSA level 50 to 99 ng/mL and ≥100 ng/mL were 43% and 36% at 10 years, respectively. Systemic progression-free survival rates in the PSA 50 to 99 ng/mL and PSA ≥100 ng/mL groups were 83% and 74% at 10 years, respectively. Estimated overall cancer-specific survival was 87% at 10 years. CONCLUSIONS. Patients with prostate cancer and a serum PSA level ≥50 ng/mL have very high-risk prostate cancer that carries a high likelihood of being pathologically advanced. Although the probability of realizing long-term survival in these high-risk patients is less than in patients with more favorable disease, 10-year survival outcomes remain excellent and argue for aggressive management of these cases.

Original languageEnglish (US)
Pages (from-to)1544-1551
Number of pages8
Issue number7
StatePublished - Oct 1 2008



  • Androgen deprivation therapy
  • External beam radiotherapy
  • Prostate cancer
  • Prostate-specific antigen
  • Radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this